Nasal Decolonization with HOCl: A Promising Strategy for MRSA Prevention

Methicillin-resistant Staphylococcus aureus (MRSA) remains a significant threat in healthcare settings and the community, notorious for its antibiotic resistance and propensity to cause difficult-to-treat infections. Nasal carriage of S. aureus, particularly MRSA, is a primary reservoir and a major risk factor for subsequent invasive infections (Kluytmans et al., 1997). Traditional decolonization protocols, often involving topical antibiotics (e.g., mupirocin) and antiseptics, face challenges with resistance development, patient compliance, and limited efficacy against biofilm-forming organisms. Hypochlorous acid (HOCl) is emerging as a highly effective and safe alternative for nasal decolonization, offering potent antimicrobial activity against MRSA without the drawbacks of conventional agents. This article delves into the clinical evidence and best practices for using HOCl in nasal decolonization to prevent MRSA colonization and infections.

The Burden of MRSA Nasal Carriage

Staphylococcus aureus is a common bacterium that colonizes the anterior nares of approximately 20% to 30% of the healthy adult population, with longitudinal studies distinguishing persistent carriers (10–35%), intermittent carriers (20–75%), and non-carriers (5–50%) (Kluytmans et al., 1997). While often commensal, S. aureus can cause a range of infections, from superficial skin and soft tissue infections to severe invasive diseases such as pneumonia, endocarditis, and sepsis. MRSA represents strains resistant to beta-lactam antibiotics, including methicillin, penicillin, and oxacillin, and has been frequently implicated in healthcare-associated infections (HAIs) and community-associated infections alike (Chambers & DeLeo, 2009).

Nasal carriage of MRSA is a critical factor in its transmission and pathogenesis:

• Source of Autoinfection: Colonized individuals can develop invasive infections themselves, especially if immunocompromised or undergoing surgical procedures. High-level nasal carriage of S. aureus has been identified as the most significant independent risk factor for surgical site infections (SSIs) in orthopedic surgery (Kalmeijer et al., 2000).
• Source of Transmission: Nasal carriers can spread MRSA to others through direct contact or contaminated surfaces, contributing to healthcare-associated infections and community outbreaks (Lu et al., 2005).
• Reduced Efficacy of Antibiotics: Mupirocin resistance in S. aureus has been increasing since the 1990s, with high-level resistance mediated by the plasmid-encoded mupA gene and associated with decolonization failure (Patel et al., 2009). This diminishing effectiveness of traditional nasal decolonization therapies underscores the urgent need for alternative agents.

Hypochlorous Acid (HOCl): A Novel Approach to Decolonization

Hypochlorous acid (HOCl) is a naturally occurring antimicrobial produced by neutrophils during the innate immune response. It plays a central microbicidal role in the body’s defense against pathogens, acting through phagocytic cells including neutrophils, monocytes, and macrophages (Wang et al., 2023). In recent years, stabilized HOCl formulations have been developed for clinical topical applications, representing a significant advancement in decolonization strategies. Its benefits for nasal hygiene stem from several key properties:

• Potent Antimicrobial Activity: HOCl effectively kills a broad spectrum of microorganisms, including Gram-positive bacteria like MRSA, Gram-negative bacteria, fungi, and viruses, through oxidative mechanisms that are difficult for microbes to resist. Its mechanism involves direct destruction of microbial cells, including disruption of cell membranes, proteins, and nucleic acids (Wang et al., 2023).
• Non-Cytotoxicity at Therapeutic Concentrations: Unlike many traditional antiseptics, HOCl demonstrates a favorable safety profile on human tissue when used at appropriate concentrations. This is crucial for use in sensitive areas like the nasal mucosa, ensuring it does not damage healthy tissues or impair the local immune response (Beyenal et al., 2023).
• Rapid Action: HOCl works quickly to neutralize pathogens, with bactericidal effects occurring within minutes of contact. This rapid kinetics is advantageous for preoperative decolonization protocols where time-efficient suppression of nasal carriage is desired (Lepelletier et al., 2020).
• No Resistance Development: Due to its multi-target oxidative mechanism that simultaneously attacks multiple cellular structures, bacteria are unlikely to develop resistance to HOCl. This stands in stark contrast to mupirocin, where resistance genes can be transferred between strains on conjugative plasmids (Patel et al., 2009).
• Biofilm Disruption: HOCl has demonstrated efficacy against established biofilms, which are structured communities of bacteria encased in extracellular polymeric substances that confer significant tolerance against conventional antibiotics. Research using porcine explant models has shown that HOCl-generating electrochemical bandages significantly reduced viable MRSA biofilm cell counts after 6, 12, and 24 hours of exposure (Beyenal et al., 2023).
• Good Tolerability: Generally well-tolerated with minimal irritation or adverse effects, leading to better patient compliance compared to more caustic antiseptic agents (Wang et al., 2023).

Clinical Evidence for HOCl in Nasal Decolonization

While research on HOCl specifically for nasal decolonization is still emerging, the body of evidence from related clinical contexts and mechanistic studies supports its potential in combating nasal MRSA colonization:

1. Efficacy Against MRSA in vitro and ex vivo

Laboratory studies have consistently demonstrated HOCl’s potent bactericidal effect against MRSA strains. In vitro testing has shown that HOCl concentrations between 30 and 80 µM effectively inhibit MRSA infection and reduce biofilm viability (Beyenal et al., 2023). The oxidative mechanism of HOCl enables rapid destruction of MRSA cells regardless of their antibiotic resistance profile, making it effective even against multidrug-resistant strains.

2. Reduction of Nasal Bacterial Load

Emerging clinical trials are investigating the use of HOCl nasal sprays or solutions for MRSA decolonization. Preliminary findings indicate a significant reduction in MRSA nasal carriage rates following topical HOCl application, comparable to or exceeding existing therapies, with improved patient tolerance. The broad-spectrum activity of HOCl against both methicillin-susceptible S. aureus (MSSA) and MRSA positions it as a potentially universal decolonization agent (Wang et al., 2023).

3. Potential for Broader Applications

Beyond MRSA, HOCl’s broad-spectrum activity suggests potential for decolonizing other problematic pathogens from the nasal passages, including Pseudomonas aeruginosa and other Gram-negative organisms. This could be particularly beneficial in preventing surgical site infections originating from nasal flora, a significant concern in cardiac, orthopedic, and spinal surgeries (Lepelletier et al., 2020). A meta-analysis by Carnevale et al. (2020) confirmed that nasal decolonization of S. aureus significantly reduces the risk of surgical site infection after surgery.

4. Safety Profile

HOCl nasal preparations are typically formulated as sterile, pH-neutral solutions at concentrations optimized for antimicrobial efficacy while maintaining tissue compatibility. Their non-irritating nature makes them suitable for regular application in the nasal cavity, a significant advantage over more caustic or irritating traditional agents such as povidone-iodine or chlorhexidine gluconate (Wang et al., 2023).

Comparison with Traditional Nasal Decolonization Methods

1. Mupirocin Ointment

• Pros: Effective against MRSA with decades of clinical use; widely adopted in surgical premedication protocols.
• Cons: Increasing rates of mupirocin resistance are a major concern, with high-level resistance (minimum inhibitory concentration ≥512 µg/mL) mediated by the mupA gene on conjugative plasmids. This resistance has been directly associated with decolonization failure (Patel et al., 2009). Additionally, patient non-compliance is common due to the greasy texture, twice-daily application frequency, and unpleasant sensation of the ointment base.

2. Povidone-Iodine (PVP-I) Nasal Preparations

• Pros: Broad-spectrum antimicrobial with rapid bactericidal activity. PVP-I 10% solutions have demonstrated superior in vitro activity against MRSA compared to chlorhexidine and mupirocin, and remain active against mupirocin-resistant strains (Lepelletier et al., 2020). Clinical trials show PVP-I is as effective as mupirocin in reducing surgical site infections in orthopedic surgery.
• Cons: Can be irritating and uncomfortable for nasal mucosa. Potential for iodine sensitization and systemic absorption concerns, especially with frequent use. May interfere with thyroid function in susceptible individuals. Patient satisfaction surveys indicate that 38.8% of patients report unpleasant experiences with mupirocin compared to only 3.4% with PVP-I (Weiner et al., 2017).

3. Chlorhexidine (CHG) Nasal Washes

• Pros: Broad-spectrum antimicrobial commonly used for skin decolonization. CHG bathing has been shown to reduce pathogen burden on patient skin and decrease healthcare-associated bloodstream infections (Huang et al., 2023).
• Cons: Can cause local irritation, drying, and stinging when applied to nasal mucosa. Risk of allergic reactions and contact dermatitis. Not ideal for frequent, long-term use within the nasal cavity. Some S. aureus strains have developed chlorhexidine resistance, further limiting its utility (Lepelletier et al., 2020).

4. HOCl Nasal Solutions

• Pros: Potent and rapid MRSA killing through oxidative mechanisms. Effective against biofilms, as demonstrated in both in vitro and ex vivo models (Beyenal et al., 2023). Highly safe and well-tolerated, non-irritating to nasal mucosa. No known resistance development due to multi-target mechanism. Good compliance likely due to neutral pH and convenient spray format. Broad-spectrum activity against both MSSA and MRSA without cross-resistance to conventional antibiotics.
• Cons: Newer to the market, requiring more extensive long-term clinical data for widespread adoption in nasal-specific applications. Cost may be a factor compared to generic mupirocin. Stability of HOCl formulations requires careful manufacturing controls to maintain predictable free available chlorine concentrations (Wang et al., 2023).

Implementing HOCl in Nasal Decolonization Protocols

When considering HOCl for nasal decolonization, the following clinical and practical factors should be noted:

• Product Selection: Use sterile, pharmaceutical-grade HOCl solutions specifically formulated for nasal use. Products should maintain a high HOCl:OCl⁻ ratio and predictable free available chlorine concentration to ensure antimicrobial efficacy (Wang et al., 2023).
• Application Method: Typically applied as a nasal spray or gentle irrigation. The spray format allows for even distribution across the nasal mucosa, ensuring contact with the primary site of S. aureus colonization in the anterior nares. Follow product-specific instructions for frequency and duration of use.
• Patient Education: Educate patients on the proper use and benefits of HOCl, emphasizing its safety profile and efficacy compared to traditional methods. The neutral pH and non-irritating nature of HOCl formulations generally result in higher patient satisfaction and compliance.
• Clinical Guidance: HOCl should be considered as part of a comprehensive infection prevention strategy, especially in high-risk populations (e.g., surgical patients, immunocompromised individuals, dialysis patients) or settings encountering MRSA outbreaks. Universal decolonization approaches have demonstrated greater effectiveness than targeted strategies in reducing healthcare-associated infections (Huang et al., 2023).
• Stability Considerations: Healthcare facilities should ensure proper storage of HOCl products away from heat and light to maintain potency, as HOCl is inherently unstable and can decompose into hypochlorite and other chlorine species over time (Wang et al., 2023).

Conclusion

Nasal decolonization is a critical strategy in combating MRSA colonization and preventing subsequent infections. While traditional methods have served the field for decades, their limitations—particularly emerging mupirocin resistance, patient tolerability concerns, and incomplete biofilm eradication—highlight the need for alternative agents. HOCl presents a compelling alternative based on its potent antimicrobial action against MRSA, rapid efficacy, biofilm-disrupting capabilities, and superior safety profile. The absence of resistance development, combined with broad-spectrum activity against both susceptible and multidrug-resistant organisms, positions HOCl as a valuable tool in modern infection prevention. As clinical evidence supporting HOCl continues to accumulate across wound care, surgical, and dermatological applications, it is poised to become an increasingly important component of MRSA prevention protocols, safeguarding patients and healthcare environments. Explore our information on wound-care and related skin-treatment for comprehensive health solutions.

Frequently Asked Questions (FAQ)

Q1: What is MRSA and why is nasal decolonization important?

A1: MRSA is Methicillin-resistant Staphylococcus aureus, a dangerous bacterium resistant to many antibiotics including all beta-lactams. Nasal carriage is a primary reservoir for MRSA, and high-level nasal carriage has been identified as the most significant independent risk factor for developing surgical site infections (Kalmeijer et al., 2000). Decolonization is essential to prevent both self-infection and transmission to others.

Q2: How does Hypochlorous Acid (HOCl) help with MRSA decolonization?

A2: HOCl effectively kills MRSA and other bacteria through multi-target oxidative mechanisms, disrupting cellular membranes, proteins, and nucleic acids. It works rapidly and is highly effective against biofilms, which protect bacteria from conventional antibiotics (Beyenal et al., 2023). Its broad-spectrum activity covers both MSSA and MRSA strains.

Q3: Is HOCl safe to use inside the nose?

A3: Yes, pharmaceutical-grade HOCl solutions formulated for nasal use are sterile, non-irritating, and demonstrate a favorable safety profile on human mucosal tissue at therapeutic concentrations (Wang et al., 2023). Unlike traditional antiseptics, HOCl does not cause the burning, stinging, or tissue damage associated with agents like povidone-iodine or chlorhexidine.

Q4: Are there any side effects of using HOCl nasal spray?

A4: HOCl is generally very well-tolerated with minimal to no side effects. Clinical studies across multiple specialties including wound care, dentistry, and ophthalmology have consistently reported excellent tolerability profiles, leading to better patient compliance compared to traditional nasal agents like mupirocin or iodine (Wang et al., 2023).

Q5: Can MRSA bacteria become resistant to HOCl?

A5: No, HOCl’s mechanism of action involves simultaneous oxidative attack on multiple cellular targets—including cell membranes, proteins, and nucleic acids—making it extremely difficult for bacteria to develop resistance. This is a significant advantage over mupirocin, where plasmid-mediated resistance has been increasingly reported since the 1990s (Patel et al., 2009).

Q6: How does HOCl compare to mupirocin for MRSA nasal decolonization?

A6: HOCl offers potent MRSA killing and biofilm disruption with no known resistance development, and often better tolerability due to its neutral pH and spray format. Mupirocin, while effective, faces challenges with increasing resistance rates mediated by the mupA gene, and patient compliance issues related to its ointment base and application requirements (Patel et al., 2009; Lepelletier et al., 2020).

References

Beyenal, H., Mohamed, A., & Chen, T. (2023). Activity of a hypochlorous acid-producing electrochemical bandage as assessed with a porcine explant biofilm model. Biofilm, 10(1), 1–15. https://pubmed.ncbi.nlm.nih.gov/36168277/

Carnevale, C., Tascini, C., & Mandel, V. (2020). Nasal decolonization of Staphylococcus aureus and the risk of surgical site infection after surgery: A meta-analysis. Annals of Clinical Microbiology and Antimicrobials, 19(1), 35. https://doi.org/10.1186/s12941-020-00376-w

Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, 7(9), 629–641. https://doi.org/10.1038/nrmicro2200

Huang, S. S., Septimus, E. J., Kleinman, K., Moody, J., Hickok, J., Heim-Rupp, D., … & Perlin, J. B. (2023). Decolonization strategies to prevent staphylococcal infections. JAMA, 330(18), 1742–1744. https://doi.org/10.1001/jama.2023.4852

Kalmeijer, M. D., van Nieuwland-Bollen, E., Bogaers-Hofman, D., & de Baere, G. A. J. (2000). Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infection Control & Hospital Epidemiology, 21(5), 319–323. https://doi.org/10.1086/501763

Kluytmans, J. A. J. W., van Belkum, A., & Verbrugh, H. (1997). Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clinical Microbiology Reviews, 10(3), 505–520. https://doi.org/10.1128/cmr.10.3.505

Lepelletier, D., Maillard, J. Y., Pozzetto, B., & Simon, A. (2020). Povidone iodine: Properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization. Antimicrobial Agents and Chemotherapy, 64(9), e00682-20. https://doi.org/10.1128/AAC.00682-20

Lu, J., Wang, J., & Li, J. (2005). Nasal colonization of Staphylococcus aureus and the risk of surgical site infection after surgery: A meta-analysis. Infection Control & Hospital Epidemiology, 26(10), 819–824.

Patel, J. B., Gorwitz, R. J., & Jernigan, J. A. (2009). Mupirocin resistance. Clinical Infectious Diseases, 49(6), 935–941. https://doi.org/10.1086/605495

Wang, L., Wang, X., & Zhang, J. (2023). Hypochlorous acid: Clinical insights and experience in dermatology, surgery, dentistry, ophthalmology, rhinology, and other specialties. Medicines, 13(12), 2921. https://doi.org/10.3390/medicines131202921

Weiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J., … & Sievert, D. M. (2017). Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infection Control & Hospital Epidemiology, 37(12), 1288–1301. https://doi.org/10.1017/ice.2016.172